By Kristy Dorsey
A UK drug development company backed by Scottish-based funds from Epidarex Capital has signed a collaboration and licensing agreement with pharmaceutical giant Novartis that could be worth up to $1.3 billion (£955 million).
Cambridge-headquartered Dunad Therapeutics – named after the ancient Scottish kingdom of Dunadd – was founded in 2020 by Patrick Gunning and Diana Kraskouskaya to further work on their protein degradation platform. This technology harnesses the natural machinery in cells to remove rogue proteins associated with disease, offering the potential to treat a range of “undruggable” targets.
The deal covers drug candidates for up to four unnamed disease targets and includes $24m (£17.6m) in upfront cash and equity, plus “significant” research funding. Should Swiss-based Novartis choose to exercise its exclusive option to commercialise any resulting products, Dunad will be eligible for up to $1.3bn in milestone payments, as well as royalties.
READ MORE: Scottish spin-out raises funds in battle to overcome cancer
Transatlantic venture capital firm Epidarex invests in early-stage life sciences firms in the US and the UK, and was founding investor in Dunad. It launched its £102m Epidarex Capital III UK fund in Edinburgh last year.
Partner Liz Roper, a board member at Dunad, said Epidarex was “delighted to see another early success” within its portfolio.
“Dunad’s rapid growth will now continue via this significant collaboration with Novartis, a leading player on protein degradation,” she added. “The agreement endorses Dunad’s highly innovative core technology and emphasises the importance of this new modality to generating new drugs for multiple diseases.”
Epidarex was an early investor in Sirakoss, a medical spin-out from the University of Aberdeen that was sold to Sweden’s OssDsign last year in a deal worth more than £8m. It also provided funding in last year’s launch of Macomics, a specialist in immune defence out of the University of Edinburgh.
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules here